CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.

ABSTRACT: Chimeric antigen receptor (CAR) T cells targeting CD19 mediate potent effects in relapsed and/or refractory pre-B cell acute lymphoblastic leukemia (B-ALL), but antigen loss is a frequent cause of resistance to CD19-targeted immunotherapy. CD22 is also expressed in most cases of B-ALL and is usually retained following CD19 loss. We report results from a phase 1 trial testing a new CD22-targeted CAR (CD22-CAR) in 21 children and adults, including 17 who were previously treated with CD19-directed immunotherapy. Dose-dependent antileukemic activity was observed, with complete remission obtained in 73% (11/15) of patients receiving ≥1 × 10⁶ CD22-CAR T cells per kg body weight, including 5 of 5 patients with CD19^dim or CD19^- B-ALL. Median remission duration was

SUBMITTER: Fry TJ 

PROVIDER: S-EPMC5774642 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature